Cargando…

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer

This study aimed to examine the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) and other clinicopathological features in HER2+ MBC patients who received first-line anti-HER2 therapy. A total of 129 patients were assigned to NLR-low and NLR-high groups based on a cutoff value of 3.0 at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Bin, Liu, Xiaoran, Li, Huiping, Song, Guohong, Di, Lijun, Jiang, Hanfang, Yan, Ying, Zhang, Ruyan, Ran, Ran, Zhang, Jiayang, Liu, Yaxin, Wang, Huan, Wang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498194/ https://www.ncbi.nlm.nih.gov/pubmed/36135052 http://dx.doi.org/10.3390/curroncol29090483

Ejemplares similares

The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study
por: Shao, Bin, et al.
Publicado: (2023)

Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
por: Jiang, Hanfang, et al.
Publicado: (2023)

The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study
por: Shao, Bin, et al.
Publicado: (2022)

Bilateral breast cancer in China: A 10‐year single‐center retrospective study (2006–2016)
por: Jiang, Hanfang, et al.
Publicado: (2021)

Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting
por: Zhang, Ruyan, et al.
Publicado: (2023)

Clinicopathological features and prognosis of patients with pregnancy‐associated breast cancer: A matched case control study
por: Zhang, Ruyan, et al.
Publicado: (2021)

Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer
por: Li, Huiping, et al.
Publicado: (2021)

Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China
por: Lei, Wen, et al.
Publicado: (2020)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer
por: Kawahara, Takashi, et al.
Publicado: (2016)

The evaluation of pretreatment neutrophil–lymphocyte ratio and derived neutrophil–lymphocyte ratio in patients with laryngeal neoplasms()
por: Eskiizmir, Gorkem, et al.
Publicado: (2018)

Pretreatment neutrophil-to-lymphocyte ratio in peripheral blood was associated with pulmonary tuberculosis retreatment
por: Yin, Yongmei, et al.
Publicado: (2016)

Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Pediatric Parotid Cancer
por: Seng, Dongjie, et al.
Publicado: (2019)

Pretreatment Neutrophil–Lymphocyte Ratio: An Independent Predictor of Survival in Patients With Hepatocellular Carcinoma
por: Gao, Fangyuan, et al.
Publicado: (2015)

Multicenter phase II study of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis
por: Li, Huiping, et al.
Publicado: (2021)

Pretreatment Neutrophil-to-Lymphocyte Ratio and Lactate Dehydrogenase Predict the Prognosis of Metastatic Cervical Cancer Treated with Combination Immunotherapy
por: Cheng, Mingxia, et al.
Publicado: (2022)

Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis
por: Liu, Xu, et al.
Publicado: (2017)

Role of the pretreatment neutrophil-to-lymphocyte ratio in the survival of primary parotid cancer patients
por: Cheng, Guangyan, et al.
Publicado: (2019)

Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet−to−Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta−analysis
por: Leng, Jiali, et al.
Publicado: (2022)

Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
por: Deng, Min, et al.
Publicado: (2017)

Pretreatment neutrophil–lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma
por: Najjar, Marc, et al.
Publicado: (2018)

Prognostic Utility of Pretreatment Neutrophil-Lymphocyte Ratio in Advanced Larynx Cancer
por: Kotha, Nikhil V, et al.
Publicado: (2021)

Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis
por: Yu, Yalian, et al.
Publicado: (2018)

Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma
por: Wang, Siqian, et al.
Publicado: (2018)

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy
por: Gao, Yiming, et al.
Publicado: (2022)

Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study
por: Gui, Xinyu, et al.
Publicado: (2020)

Prognostic Relevance of Pretreatment Peripheral Neutrophil Count and Neutrophil-to-lymphocyte Ratio in Primary Cutaneous Angiosarcoma
por: AWAJI, Kentaro, et al.
Publicado: (2021)

Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer
por: Wang, Xin, et al.
Publicado: (2016)

Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients
por: Wang, Jinhao, et al.
Publicado: (2023)

Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer
por: Zhao, Guanghui, et al.
Publicado: (2020)

The Pretreatment Neutrophil/Lymphocyte Ratio Is Associated with All-Cause Mortality in Black and White Patients with Non-metastatic Breast Cancer
por: Rimando, Joseph, et al.
Publicado: (2016)

Pretreatment neutrophil to lymphocyte and platelet to lymphocyte ratios as predictive factors for the survival of cervical adenocarcinoma patients
por: Jonska-Gmyrek, Joanna, et al.
Publicado: (2018)

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
por: LIANG, XU, et al.
Publicado: (2015)

Prognostic Value of Neutrophil–Lymphocyte Ratio, Platelet–Lymphocyte Ratio, and Combined Neutrophil–Lymphocyte Ratio and Platelet–Lymphocyte Ratio in Stage IV Advanced Gastric Cancer
por: Wang, Huan, et al.
Publicado: (2020)

Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Monocyte-to-Lymphocyte Ratio in Depression: An Updated Systematic Review and Meta-Analysis
por: Cheng, Yanwei, et al.
Publicado: (2022)

The Role of Pretreatment Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in the Diagnosis of Breast Cancer: Predicting Lymph Node Metastasis
por: Eroglu, Aydan, et al.
Publicado: (2013)

Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma
por: Lee, Su-Min, et al.
Publicado: (2015)

Pretreatment neutrophil‐to‐lymphocyte ratio as a potential prognostic biomarker for newly diagnosed patients with metastatic castration‐sensitive prostate cancer
por: Salah, Samer, et al.
Publicado: (2021)

Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
por: Rottier, Pauline, et al.
Publicado: (2023)

The clinical relevance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in chronic obstructive pulmonary disease with lung cancer
por: Ma, Aiping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n7f1nmf48p4bdm6p9ma6emil81